Bacil Pharma

Bacil Pharma Enterprise Value

The Enterprise Value (EV) of Bacil Pharma (524516.BO) as of Nov 4, 2026 is 551.52 M INR. In the previous year, Enterprise Value (EV) was 524.59 M INR — a change of 5.13% (higher).

Enterprise Value

551.52 MINR

YoY

5.13%

Last updated:

Enterprise Value (EV) of Bacil Pharma is 2026 551.52 M INR. Enterprise Value (EV) of Bacil Pharma was 2025 524.59 M INR. It decreases by 5.13% higher compared to the previous year.

The Bacil Pharma Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
551.52 M INR
Jan 1, 2020
551.52 M INR
Jan 1, 2021
551.52 M INR
Jan 1, 2022
551.52 M INR
Jan 1, 2023
549.53 M INR
Jan 1, 2024
552.09 M INR
Jan 1, 2025
524.59 M INR
Jan 1, 2026
551.52 M INR
The Bacil Pharma Enterprise Value history
YEAREnterprise ValueYoY
551.52 MINR+5.13%
524.59 MINR-4.98%
552.09 MINR+0.47%
549.53 MINR-0.36%
551.52 MINR0.00%
551.52 MINR0.00%
551.52 MINR0.00%
551.52 MINR0.00%
551.52 MINR-0.55%
554.58 MINR+0.06%
554.24 MINR+0.23%
552.95 MINR+0.11%
552.32 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bacil Pharma Stock analysis

What does Bacil Pharma do? Bacil Pharma Ltd, identified by the ticker symbol 524516.BO and the ISIN INE711D01018, is a prominent entity within the Indian healthcare sector. Headquartered in Mumbai, Maharashtra, the company has established itself as a significant player in the pharmaceutical industry. Bacil Pharma Ltd specializes in the comprehensive manufacturing and distribution of a diverse range of products, including pharmaceuticals, medicinal chemicals, and botanical products. This strategic focus on both synthetic medicinal compounds and natural botanical ingredients allows the company to cater to a broad spectrum of therapeutic needs and market demands. The firm's operational base in Mumbai, one of India's major financial and commercial hubs, provides it with substantial logistical advantages and access to a well-developed infrastructure network, which is crucial for the timely distribution of healthcare products across the country and potentially into international markets. The company's journey in the public domain began with its initial public offering on March 15, 1994. This milestone marked a significant step in its corporate evolution, enabling it to raise capital for expansion, research, and development activities. Since its listing, Bacil Pharma Ltd has continued to refine its product portfolio and manufacturing capabilities, maintaining a steady presence in the competitive pharmaceutical landscape. The company's official website, http://www.bacilpharma.com/, serves as a primary resource for stakeholders, investors, and customers seeking detailed information about its product lines, corporate governance, and business operations. By engaging in the manufacture and sale of both medicinal and botanical products, Bacil Pharma Ltd demonstrates a commitment to integrating traditional herbal wisdom with modern pharmaceutical science. This dual approach not only reflects the growing global interest in natural health solutions but also positions the company to capitalize on emerging trends in preventive healthcare and wellness. As a listed entity on the Indian stock exchange, Bacil Pharma Ltd is subject to regulatory oversight and disclosure requirements, ensuring transparency and accountability to its shareholders. The company's enduring presence in the market since the mid-1990s underscores its resilience and adaptability in a dynamic industry characterized by rapid technological advancements and evolving regulatory frameworks. Through its continued focus on quality manufacturing and product innovation, Bacil Pharma Ltd aims to sustain its growth trajectory and contribute to the broader healthcare ecosystem in India and beyond. Bacil Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bacil Pharma stock

Enterprise Value (EV) of Bacil Pharma is 551.52 M INR in 2026.

Enterprise Value (EV) of Bacil Pharma changed from 524.59 M INR to 551.52 M INR, representing a 5.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Bacil Pharma since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s INR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' INR varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Bacil Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bacil Pharma

All Key Metrics — Bacil Pharma